| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/09/2009 | US20090175876 Methods of using phhla2 to co-stimulate t-cells |
| 07/09/2009 | US20090175875 Molecules and Methods for Modulating Complement Component |
| 07/09/2009 | US20090175874 Novel interleukin-1 receptor intracellular ligand proteins and inhibitors of ligand binding |
| 07/09/2009 | US20090175873 Inhibiting tumor cell invasion, metastasis and angiogenesis |
| 07/09/2009 | US20090175872 Treatment of Conditions Involving Demyelination |
| 07/09/2009 | US20090175871 Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors |
| 07/09/2009 | US20090175870 Ykl-40 monoclonal authority |
| 07/09/2009 | US20090175869 Pulsatile Dosing of Gossypol for Treatment of Disease |
| 07/09/2009 | US20090175868 IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| 07/09/2009 | US20090175867 Single-Chain Multivalent Binding Proteins with Effector Function |
| 07/09/2009 | US20090175866 Treatment of b-cell malignancies |
| 07/09/2009 | US20090175865 using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells |
| 07/09/2009 | US20090175864 Exhibiting improved activity relative to the native insulin-like growth factor 1 and II polypeptide; The fusion component F is selected from the group consisting of a human IgG constant region, Fc domain, and heavy chain; muscle atrophy |
| 07/09/2009 | US20090175863 Agents targeting cd138 and uses thereof |
| 07/09/2009 | US20090175862 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 07/09/2009 | US20090175861 Use of a b-cell-depleting antibody for treatment of polyoma virus infections |
| 07/09/2009 | US20090175860 Compositions and Methods of Use for Antibodies of c-Met |
| 07/09/2009 | US20090175859 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 07/09/2009 | US20090175858 Crystalline EGFR - matuzumab complex and matuzumab mimetics obtained thereof |
| 07/09/2009 | US20090175857 Human Antibodies That Bind Human IL-12 And Methods For Producing |
| 07/09/2009 | US20090175856 Anti-Proliferative Combination Therapy Using Certain Platinum-Based Chemotherapeutic Agents and EGFR Inhibitors or Pyrimidine Analogues |
| 07/09/2009 | US20090175855 Novel compositions and methods for the treatment of immune related diseases |
| 07/09/2009 | US20090175854 Methods of using death receptor ligands and CD20 antibodies |
| 07/09/2009 | US20090175853 Method for treating amyloid disease |
| 07/09/2009 | US20090175852 Imidazopyrazines as protein kinase inhibitors |
| 07/09/2009 | US20090175851 Bivalent, bispecific antibodies |
| 07/09/2009 | US20090175850 NOGO Receptor Homologs |
| 07/09/2009 | US20090175849 NOTCH inhibition in the treatment or prevention of atherosclerosis |
| 07/09/2009 | US20090175848 Modulation of the Cooperativity Between the Ion Channels TRPM5 and TRPA1 |
| 07/09/2009 | US20090175847 Humanized antibodies to ab (20-42) globulomer and uses thereof |
| 07/09/2009 | US20090175846 Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof |
| 07/09/2009 | US20090175845 Methods for identifying compounds that modulate phb domain protein activity and compositions thereof |
| 07/09/2009 | US20090175844 Method of diagnosing bladder cancer |
| 07/09/2009 | US20090175823 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 07/09/2009 | US20090175796 Antibodies and related molecules that bind to 24p4c12 proteins |
| 07/09/2009 | US20090175791 Anti-VEGF Antibody Compositions and Methods |
| 07/09/2009 | US20090175789 Antibody raised against the ldl receptor |
| 07/09/2009 | US20090175784 Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
| 07/09/2009 | CA2744910A1 Replication-defective arenavirus vectors |
| 07/09/2009 | CA2710984A1 Treatment and prophylaxis of amyloidosis |
| 07/09/2009 | CA2710775A1 Formulation |
| 07/09/2009 | CA2710418A1 Stabilized formulations of peptides and proteins |
| 07/09/2009 | CA2710375A1 Treatment of orthopedic conditions |
| 07/09/2009 | CA2710252A1 Methods for the treatment of gout |
| 07/09/2009 | CA2710082A1 Methods for using and identifying modulators of delta-like 4 |
| 07/09/2009 | CA2709380A1 Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain |
| 07/09/2009 | CA2709354A1 Anti-amyloid antibodies and uses thereof |
| 07/09/2009 | CA2708648A1 Fdf03 antibodies and uses thereof |
| 07/09/2009 | CA2708627A1 High concentration antibody-containing liquid formulation |
| 07/09/2009 | CA2707791A1 Therapy of rituximab-refractory rheumatoid arthritis patients |
| 07/09/2009 | CA2706899A1 B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| 07/09/2009 | CA2704283A1 Vaccine |
| 07/08/2009 | EP2077325A1 Monoclonal antibody and use thereof |
| 07/08/2009 | EP2077282A2 Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| 07/08/2009 | EP2077281A1 Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| 07/08/2009 | EP2077279A1 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 07/08/2009 | EP2077277A1 Use of mammalian cytokine; related reagents |
| 07/08/2009 | EP2077121A1 Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder |
| 07/08/2009 | EP2077120A2 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient |
| 07/08/2009 | EP2077117A1 Agent exhibiting immunoregulatory properties and the use thereof for treating autoimmune diseases |
| 07/08/2009 | EP2076603A2 A serum-free virus propagation platform for a virus vaccine candidate |
| 07/08/2009 | EP2076542A1 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 07/08/2009 | EP2076539A2 Antibody molecules which bind il-17a and il-17f |
| 07/08/2009 | EP2076538A2 Materials and methods for improved immunoglycoproteins |
| 07/08/2009 | EP2076289A2 Methods for treating cancer resistant to erbb therapeutics |
| 07/08/2009 | EP2076287A2 Methods and compositions with reduced opalescence |
| 07/08/2009 | EP2076286A2 Methods of reducing phosphate absorption |
| 07/08/2009 | EP2076285A2 Antibody antagonists of interleukin-13 receptor 1 |
| 07/08/2009 | EP2076284A2 Methods for treating, preventing and diagnosing porcine ttv infection |
| 07/08/2009 | EP2076283A2 Methods of disrupting quorum sensing to affect microbial population cell density |
| 07/08/2009 | EP2076282A1 Novel antagonists of the toll-like receptor 4 |
| 07/08/2009 | EP2076280A2 Feline influenza vaccine and method of use |
| 07/08/2009 | EP1962889B1 Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof |
| 07/08/2009 | EP1732588B1 Modulation of nkg2d |
| 07/08/2009 | EP1434596B1 Enhancement of immune responses by agonist 4-1bb-antibodies |
| 07/08/2009 | EP1383927B1 New polynucleotides and polypeptides of the erythropoietin gene |
| 07/08/2009 | EP1371730B1 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 07/08/2009 | EP1265929B1 Anti-c2/c2a inhibitors of complement activation |
| 07/08/2009 | EP1114172B1 Transfer method for specific cellular localisation of nucleic acids |
| 07/08/2009 | EP1009429B1 Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| 07/08/2009 | EP0669988B2 Angiogenesis inhibitory antibodies |
| 07/08/2009 | CN101478988A Combination therapy product and uses thereof |
| 07/08/2009 | CN101478987A Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminum |
| 07/08/2009 | CN101478986A A method for the production of hydrolyzed allergen |
| 07/08/2009 | CN101478985A A novel virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| 07/08/2009 | CN101478984A Compositions and methods for treating parasitic infections |
| 07/08/2009 | CN101474403A Oil adjuvant of inactivated vaccine |
| 07/08/2009 | CN101474402A Immunomodulator containing activated product of interleukin gene |
| 07/08/2009 | CN101474401A Method for producing concentrated inactivate vaccine for newcastle disease |
| 07/08/2009 | CN101474400A Human streptococcus mutans genetic engineering vaccine for decayed tooth and preparation method thereof |
| 07/08/2009 | CN100510080C Malignant malarial parasite new antigen candidate gene pfMAg |
| 07/08/2009 | CN100510079C Malignant malarial parasite dynein gene |
| 07/08/2009 | CN100510073C Tryptase inhibitor |
| 07/08/2009 | CN100510068C A soluble complex comprising a retroviral surface glycoprotein |
| 07/08/2009 | CN100510060C Method of extended culture for antigen-specific cytotoxic t lymphocytes |
| 07/08/2009 | CN100509844C Variants of the major allergen phl p 1 from timothy grass |
| 07/08/2009 | CN100509057C Antigen arrays for treatment of bone disease |
| 07/08/2009 | CN100509056C Vaccines including as an adjuvant type 1 IFN and process related thereto |
| 07/07/2009 | USRE40832 An adenovirus type 36 (Ad-36) vaccine formualtion suitable for administration to a patient for reducing cholesterol and triglyceride level ( cause of obesity); killed Ad-36, an inactivated Ad-36, a protein or peptide sequence including an Ad-36 coat protein or fragment |
| 07/07/2009 | USRE40831 Passive immunotherapy; hybridoma cell line and antibodies produced by the cell lines; prevention and treatment of HBV infection |